Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) traded down 8.9% on Tuesday . The company traded as low as $1.36 and last traded at $1.53. 5,120,275 shares were traded during mid-day trading, a decline of 6% from the average session volume of 5,419,914 shares. The stock had previously closed at $1.68.
Tevogen Bio Price Performance
The firm's 50-day moving average is $1.21 and its two-hundred day moving average is $1.01.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Tevogen Bio stock. HGC Investment Management Inc. bought a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 223,077 shares of the company's stock, valued at approximately $82,000. HGC Investment Management Inc. owned about 0.13% of Tevogen Bio as of its most recent filing with the Securities and Exchange Commission.
Tevogen Bio Company Profile
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
See Also
Before you consider Tevogen Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.
While Tevogen Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
